Onconic Therapeutics Inc.

This Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps k…

This study tests a new drug called JPI-547 combined with irinotecan for people with advanced stomach cancer that has come back or spread after at least two prior treatments. The goal is to see if the combination is safe and can shrink tumors. About 49 adults with good performance…

This study tests a new drug called JP-1366 for people with non-erosive gastroesophageal reflux disease (NERD), a condition causing heartburn without visible damage to the esophagus. About 321 adults will take either JP-1366 or a placebo daily. The main goal is to see if the drug …

This early-stage study looks at how food and ethnic background affect the way a new drug, JPI-547, moves through the body. It involves 36 healthy men of Korean, Caucasian, or Chinese descent who take a single dose. The goal is to gather safety and drug-level data, not to treat an…